NYSE$COR
Cencora Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
AmerisourceBergen reported a revenue increase of 5.4% year-over-year, with GAAP diluted EPS of $2.33 and adjusted diluted EPS of $2.71. The adjusted diluted EPS guidance range was raised to $11.50 to $11.75 for fiscal year 2023.
AmerisourceBergen reported a solid first quarter with a 5.4% increase in revenue to $62.8 billion. GAAP diluted EPS was $2.33, and adjusted diluted EPS increased by 5.0% to $2.71. The company raised its adjusted diluted EPS guidance for fiscal year 2023 to $11.50 to $11.75.
- Revenue increased by 5.4% year-over-year to $62.8 billion.
- GAAP diluted EPS was $2.33, compared to $2.13 in the prior year.
- Adjusted diluted EPS increased by 5.0% to $2.71, from $2.58 in the prior year.
- Adjusted diluted EPS guidance was raised to $11.50 to $11.75 for fiscal year 2023.
Headline financials
Revenue & EPS history
Cencora · Revenue · Quarterly
$62.8B
Forward guidance
AmerisourceBergen is updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-than-expected close of the Company’s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower expectations for COVID treatment contributions for the year. Adjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75.
Tailwinds
- Adjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from the previous range of $11.30 to $11.60
- On a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised from the previous range of 4 to 7 percent
- Excluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11 percent, raised from the previous range of 7 to 9 percent
- On a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent
- International Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth, up from the previous range of a 7 to 3 percent decline
Headwinds
- U.S. Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the previous range of 2 percent to 4 percent.
- Expectations for segment operating income growth excluding COVID-19 contributions remain unchanged.
- All other previously communicated aspects of the Company’s fiscal year 2023 financial guidance and assumptions remain the same.
- Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing and amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot be determined, are unavailable and cannot be reasonably estimated.
- Company does not provide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
-0.1%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.4%
Avg return
30 days after
48%
35 / 73 earnings
Positive
+7.8%
Q2 2019
Best reaction
-18.4%
Q2 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -18.4% | -16.6% | -10.1% | |
| Q1 2026 | -5.9% | +0.4% | -0.9% | |
| Q4 2025 | +2.9% | +5.8% | -1.4% | |
| Q3 2025 | -2.9% | -0.6% | +0.1% | |
| Q2 2025 | +4.6% | -4.3% | -0.6% | |
| Q1 2025 | +0.7% | -2.1% | +1.2% | |
| Q4 2024 | +5.9% | +6.5% | +4.0% | |
| Q3 2024 | +5.8% | +4.4% | +3.7% | |
| Q2 2024 | -6.0% | -6.3% | -5.2% | |
| Q1 2024 | +7.4% | +6.2% | +7.5% | |
| Q4 2023 | +4.2% | +4.7% | +9.0% | |
| Q3 2023 | +1.2% | -1.3% | -7.5% | |
| Q2 2023 | +0.1% | +0.7% | +3.5% | |
| Q1 2023 | -6.2% | -8.6% | -7.6% | |
| Q4 2022 | +4.4% | +3.1% | +12.4% | |
| Q3 2022 | -2.5% | -1.5% | +3.4% | |
| Q2 2022 | +2.9% | +4.4% | -2.5% | |
| Q1 2022 | +0.2% | +1.3% | +7.0% | |
| Q4 2021 | -0.6% | -2.8% | -9.0% | |
| Q3 2021 | -1.5% | -2.8% | +1.2% | |
| Q2 2021 | -6.5% | -2.1% | -7.1% | |
| Q1 2021 | +3.9% | +1.8% | -0.7% | |
| Q4 2020 | -1.0% | +4.8% | -1.9% | |
| Q3 2020 | -3.0% | -1.6% | -7.7% | |
| Q2 2020 | +3.0% | +3.6% | +15.8% | |
| Q1 2020 | -4.8% | -2.0% | -6.2% | |
| Q4 2019 | +1.6% | +1.0% | +4.2% | |
| Q3 2019 | +3.8% | -3.5% | -5.6% | |
| Q2 2019 | +7.8% | +5.5% | +6.1% | |
| Q1 2019 | +6.7% | +9.2% | +5.7% | |
| Q4 2018 | -2.3% | +0.3% | -2.9% | |
| Q3 2018 | +1.9% | +5.0% | +13.2% | |
| Q2 2018 | -4.3% | -5.1% | -6.6% | |
| Q1 2018 | +2.5% | -2.9% | +4.7% | |
| Q4 2017 | -2.4% | -2.2% | +10.9% | |
| Q3 2017 | -11.4% | -12.0% | -12.1% | |
| Q2 2017 | +3.9% | +5.9% | +13.2% | |
| Q1 2017 | +6.0% | +6.8% | +9.9% | |
| Q4 2016 | +3.6% | +3.1% | +12.9% | |
| Q3 2016 | +5.1% | +4.5% | +1.9% | |
| Q2 2016 | -9.2% | — | — | |
| Q1 2016 | -3.7% | — | — | |
| Q4 2015 | -1.0% | — | — | |
| Q3 2015 | -5.4% | — | — | |
| Q2 2015 | +1.9% | — | — | |
| Q1 2015 | +0.4% | — | — | |
| Q4 2014 | +7.1% | — | — | |
| Q3 2014 | +3.7% | — | — | |
| Q2 2014 | -3.1% | — | — | |
| Q1 2014 | -4.3% | — | — | |
| Q4 2013 | +1.8% | — | — | |
| Q3 2013 | -0.0% | — | — | |
| Q2 2013 | -4.6% | — | — | |
| Q1 2013 | -5.1% | — | — | |
| Q4 2012 | -0.6% | — | — | |
| Q3 2012 | +2.7% | — | — | |
| Q2 2012 | -1.2% | — | — | |
| Q1 2012 | +2.4% | — | — | |
| Q4 2011 | -1.0% | — | — | |
| Q3 2011 | -0.5% | — | — | |
| Q2 2011 | +2.9% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q4 2010 | -0.5% | — | — | |
| Q3 2010 | -0.7% | — | — | |
| Q2 2010 | +1.0% | — | — | |
| Q1 2009 | -1.7% | — | — | |
| Q1 2010 | +1.2% | — | — | |
| Q4 2009 | -0.6% | — | — | |
| Q2 2009 | -0.6% | — | — | |
| Q4 2007 | -0.6% | — | — | |
| Q3 2008 | -0.5% | — | — | |
| Q3 2009 | -0.5% | — | — | |
| Q4 2008 | -0.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro